V181

Vaccine

Phase 3Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Phase 3underway

Evidence outlook · registrational

Dengue: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2031-09-06.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Dengue
NCT07013487 · Merck Sharp & Dohme LLC
2025-06-11 – 2031-09-06 · Healthy
What this study did
Phase 2 (2)
Dengue
NCT05507450 · Merck Sharp & Dohme LLC
2022-09-07 – 2024-05-07 · Dengue Disease, Dengue Virus
What this study did

Competitive landscape

This drug's own stage for Dengue: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
V181: this drugPhase 3Vaccine—not yet gradedNo reviewed efficacy summary in this indication
EYU688Phase 2Small moleculeDengue NS4Bnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow V181 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2031 (1)
September 2031 (1)
Phase 3DengueActive not recruiting
Est. primary completion 2031-09-06 · NCT07013487 · CT.gov ↗
What to watch

See the full readout calendar ↗